Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
79.50
+2.91 (3.80%)
Feb 24, 2026, 4:00 PM EST - Market closed
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
Biologic Therapeutic Candidates | 200.00K | 1.80M | 1.32M | 7.23M |
Biologic Therapeutic Candidates Growth | -88.89% | 36.88% | -81.81% | - |
| 200.00K | 1.80M | 1.32M | 7.23M |
| -88.89% | 36.88% | -81.81% | - |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
| 200.00K | 1.80M | 1.32M | 7.23M |
| -88.89% | 36.88% | -81.81% | - |
| 200.00K | 1.80M | 1.32M | 7.23M |
| -88.89% | 36.88% | -81.81% | - |
Source: S&P Global Market Intelligence.
